大麻素类药物用于肾衰竭患者症状管理:一篇叙述性综述
本叙述性综述总结了大麻素类药物的药理学与药代动力学,以及其在肾病或肾衰竭患者中用于缓解瘙痒、恶心、失眠、慢性神经病理性疼痛、厌食和不宁腿综合征等常见症状的现有证据。目前尚无法对症状性肾衰竭患者进行基于证据的大麻素处方;鉴于该人群症状负担重,亟需了解此类药物在该人群中的耐受性与安全性,并最终开展稳健的随机对照试验以确定其缓解症状是否有效。
要点
- 肾衰竭患者症状负担重,现有治疗有限,常导致症状缓解不充分。
- 大麻素受体CB1和CB2广泛表达于神经与免疫系统,外源性大麻素可产生抗焦虑、止吐、镇痛和抗炎作用。
- 目前尚无法对症状性肾衰竭患者进行基于证据的大麻素处方,亟需随机对照试验。
核心结论
- 目前尚无法对症状性肾衰竭患者进行基于证据的大麻素处方。
- 鉴于肾衰竭患者症状负担重,亟需了解此类药物在该人群中的耐受性与安全性,并最终开展稳健的随机对照试验以确定其缓解症状是否有效。
研究设计与样本
- 叙述性综述,总结大麻素类药物的药理学与药代动力学及其在肾病或肾衰竭患者中用于缓解症状的现有证据。
主要发现
- 大麻素受体CB1和CB2广泛表达于全身,包括神经与免疫系统,外源性大麻素可产生抗焦虑、止吐、镇痛和抗炎作用。
- 基于已知生理作用及其他患者人群中的成功研究,大麻素可能被视为治疗肾衰竭患者多种常见症状的潜在疗法,包括瘙痒、恶心、失眠、慢性神经病理性疼痛、厌食和不宁腿综合征。
- 目前,尽管这些药物在其他患者人群中显示出 varying efficacy 且安全性可接受,但尚无法对症状性肾衰竭患者进行基于证据的大麻素处方。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
People with kidney failure can experience a range of symptoms that lead to suffering and poor quality of life. Available therapies are limited, and evidence for new treatment options is sparse, often resulting in incomplete relief of symptoms. There is growing interest in the potential for cannabinoids, including cannabidiol and tetrahydrocannabinol, to treat symptoms across a wide range of chronic diseases. As legal prohibitions are withdrawn or minimized in many jurisdictions, patients are increasingly able to access these agents. Cannabinoid receptors, CB1 and CB2, are widely expressed in the body, including within the nervous and immune systems, and exogenous cannabinoids can have anxiolytic, antiemetic, analgesic, and anti-inflammatory effects. Considering their known physiologic actions and successful studies in other patient populations, cannabinoids may be viewed as potential therapies for a variety of common symptoms affecting those with kidney failure, including pruritus, nausea, insomnia, chronic neuropathic pain, anorexia, and restless legs syndrome. In this review, we summarize the pharmacology and pharmacokinetics of cannabinoids, along with what is known about the use of cannabinoids for symptom relief in those with kidney disease, and the evidence available concerning their role in management of common symptoms. Presently, although these agents show varying efficacy with a reasonable safety profile in other patient populations, evidence-based prescribing of cannabinoids for people with symptomatic kidney failure is not possible. Given the symptom burden experienced by individuals with kidney failure, there is an urgent need to understand the tolerability and safety of these agents in this population, which must ultimately be followed by robust, randomized controlled trials to determine if they are effective for symptom relief.
引用
- Worth H, O'Hara DV, Agarwal N, et al. Cannabinoids for Symptom Management in Patients with Kidney Failure: A Narrative Review. Clin J Am Soc Nephrol. 2022. PMID: 34987023. doi:10.2215/CJN.11560821
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。